More recently, gonadotropin-releasing hormone (GnRH) agonists have been applied to that end, primarily in high responder patients, to prevent early onset ovarian hyperstimulation syndrome (OHSS), due to the induction of more physiologic LH and FSH releases (Griesinger et al., 2006; Humaidan et al., 2011). Here, BRD2 is linked to ovarian hyperstimulation syndrome.